There may be another anti-obesity drug on the market soon. La Jolla-based Orexigen Therapeutics Inc. resubmitted its application for its drug, Contrave, to the Food and Drug Administration.
The application process will likely take up to 6 months, according to the San Diego Business Journal.
The business publication reported this is the second time Orexigen has applied for regulatory approval for Contrave. It said the company was refused in 2001 due to concerns of possible cardiovascular risk. Orexigen has conducted additional clinical trials since then with positive interim result, the SDBJ reported.